Literature DB >> 19747201

Increased prevalence of prolonged QT interval in males with primary or secondary hypogonadism: a pilot study.

F Pecori Giraldi1, P M Toja, B Filippini, J Michailidis, M Scacchi, M Stramba Badiale, F Cavagnini.   

Abstract

Symptoms and signs of male hypogonadism span all organ systems, including the cardiovascular apparatus. The electrocardiographic QT interval reflects cardiac ventricular repolarization and, if prolonged, increases the risk of malignant arrhythmias. QT interval duration is similar in boys and girls during childhood, but shortens in males after puberty and experimental studies suggest that testosterone is a major contributor to shortening of QT interval in men. The aim of the present pilot study was to assess the duration of ventricular repolarization in adult males with primary or secondary hypogonadism. Standard ECG recordings were performed in 26 men (mean age 39.2 +/- 2.17 years) with pituitary or testicular hypogonadism and repeated in 15 patients during testosterone replacement. Twenty-six age-matched control men were also analysed. Measured QT intervals were corrected for heart rate according to Bazzett's formula (QTc = QT/radical RR interval). The prevalence of prolonged QTc was considerably higher in hypogonadal patients (four of 26 men) than in control men (none, p < 0.05) and in the general, healthy population (<2.5%). QTc interval normalized on hormone replacement therapy in the four patients presenting prolonged QTc in the hypogonadal state. Heart rate and left ventricular mass did not differ among the two groups and no known QT-prolonging factor was apparent in patients with abnormal QTc interval. In conclusion, a high number prolonged QT interval measurements was observed in hypogonadal men who may therefore be at increased risk for cardiac arrhythmias. This observation reveals an additional feature of male hypogonadism, which may benefit from testosterone replacement therapy.

Entities:  

Mesh:

Year:  2009        PMID: 19747201     DOI: 10.1111/j.1365-2605.2009.00985.x

Source DB:  PubMed          Journal:  Int J Androl        ISSN: 0105-6263


  10 in total

Review 1.  Sex hormones and the QT interval: a review.

Authors:  Tara Sedlak; Chrisandra Shufelt; Carlos Iribarren; C Noel Bairey Merz
Journal:  J Womens Health (Larchmt)       Date:  2012-06-04       Impact factor: 2.681

Review 2.  Male hormonal contraception: potential risks and benefits.

Authors:  Niloufar Ilani; Ronald S Swerdloff; Christina Wang
Journal:  Rev Endocr Metab Disord       Date:  2011-06       Impact factor: 6.514

Review 3.  Testosterone, myocardial function, and mortality.

Authors:  Vittorio Emanuele Bianchi
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

4.  Vascular dysfunction and increased cardiovascular risk in hypospadias.

Authors:  Angela K Lucas-Herald; Augusto C Montezano; Rheure Alves-Lopes; Laura Haddow; Malika Alimussina; Stuart O'Toole; Martyn Flett; Boma Lee; S Basith Amjad; Mairi Steven; Katriona Brooksbank; Linsay McCallum; Christian Delles; Sandosh Padmanabhan; S Faisal Ahmed; Rhian M Touyz
Journal:  Eur Heart J       Date:  2022-05-14       Impact factor: 35.855

5.  Effect of Degarelix, a Gonadotropin-Releasing Hormone Receptor Antagonist for the Treatment of Prostate Cancer, on Cardiac Repolarisation in a Randomised, Placebo and Active Comparator Controlled Thorough QT/QTc Trial in Healthy Men.

Authors:  Håkan Olsson; Niclas Petri; Lars Erichsen; Anders Malmberg; Lars Grundemar
Journal:  Clin Drug Investig       Date:  2017-09       Impact factor: 2.859

Review 6.  Randomized controlled trials - mechanistic studies of testosterone and the cardiovascular system.

Authors:  T Hugh Jones; Daniel M Kelly
Journal:  Asian J Androl       Date:  2018 Mar-Apr       Impact factor: 3.285

7.  Changes in left ventricular repolarization after short-term testosterone replacement therapy in hypogonadal males.

Authors:  G Piccirillo; F Moscucci; R Pofi; G D'Alessandro; M Minnetti; A M Isidori; D Francomano; A Lenzi; P E Puddu; J Alexandre; D Magrì; A Aversa
Journal:  J Endocrinol Invest       Date:  2019-03-05       Impact factor: 4.256

Review 8.  Testosterone and the cardiovascular system: a comprehensive review of the clinical literature.

Authors:  Peyman Mesbah Oskui; William J French; Michael J Herring; Guy S Mayeda; Steven Burstein; Robert A Kloner
Journal:  J Am Heart Assoc       Date:  2013-11-15       Impact factor: 5.501

9.  Evolution of Electrocardiographic Repolarization Parameters During Antiandrogen Therapy in Patients with Prostate Cancer and Hypogonadism.

Authors:  Andrei Cristian Dan Gheorghe; Ana Ciobanu; Andreea Simona Hodorogea; George Daniel Radavoi; Viorel Jinga; Ioan Tiberiu Nanea; Gabriela Silvia Gheorghe
Journal:  Cardiovasc Toxicol       Date:  2020-08       Impact factor: 3.231

Review 10.  Cardiovascular risk and testosterone - from subclinical atherosclerosis to lipoprotein function to heart failure.

Authors:  Baris Gencer; Marco Bonomi; Maria Pia Adorni; Cesare R Sirtori; François Mach; Massimiliano Ruscica
Journal:  Rev Endocr Metab Disord       Date:  2021-02-22       Impact factor: 6.514

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.